ENTERO

New Filing detected. See link for details.

Entero Healthcare Solutions Limited announced the uploading of the audio recording for its Investors/Analyst Earnings Call/Conference Call held for the Audited Financial Results for the Quarter and Year ended March 31, 2026. The recording is accessible via a provided link, and the transcript will be shared with stock exchanges and uploaded on the company's website shortly.

Standalone Revenue ₹78.93Cr vs ₹72.30Cr (▲9.2% YoY). Standalone EBITDA swung to a profit of ₹17.42Cr from a loss of ₹33.15Cr in the previous year. Standalone PAT swung to a profit of ₹13.42Cr from a loss of ₹27.81Cr in the previous year. EBITDA Margin improved to 22.1% from -45.8%. The board also approved the re-appointment of three Independent Directors and the Internal Auditor, along with the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals.

The Board of Directors of Entero Healthcare Solutions Limited approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026, with an unmodified auditor opinion. Key decisions included the re-appointment of three Non-Executive Independent Directors and the Internal Auditor, allotment and grant of shares/options under the Employee Stock Option Plan 2023, and the announcement of the 8th Annual General Meeting on August 19, 2026. The company also announced the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals.

Standalone Revenue ₹3,482.41 Million vs ₹4,086.70 Million (▼14.8% YoY). Standalone EBITDA loss narrowed from ₹774.27 Million in the previous year to ₹672.07 Million. Standalone PAT ₹268.75 Million vs ₹191.81 Million (▲40.1% YoY). EBITDA Margin -19.3% vs -18.9% (▼36bps). The PAT increase was significantly influenced by a reduction in exceptional items from ₹470.81 Million to ₹44.97 Million.

Entero Healthcare Solutions Limited reported Standalone Revenue of ₹78.93Cr vs ₹72.30Cr (▲9.17% YoY) for the quarter ended March 31, 2026. EBITDA stood at ₹-13.54Cr vs ₹-59.02Cr (▲77.06% YoY, becoming less negative). PAT shifted from a loss of ₹-27.81Cr to a profit of ₹13.42Cr. EBITDA Margin improved from -81.63% to -17.15% (▲6448 bps). The board also approved re-appointment of Independent Directors and Internal Auditor, ESOP allotments/grants, scheduled the 8th AGM on August 19, 2026, and approved the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals.

Standalone Revenue ₹78.93 Cr vs ₹72.30 Cr (▲9.17% YoY), EBITDA -₹13.54 Cr vs -₹11.94 Cr (▼13.37% YoY), PAT ₹13.42 Cr vs -₹27.81 Cr (▲148.25% YoY, from loss to profit). EBITDA Margin -17.15% vs -16.51% (▼64bps).

Entero Healthcare Solutions reported standalone Q4 FY26 results: Revenue ₹789.32 Million vs ₹723.02 Million (▲9.2% YoY), EBITDA loss significantly reduced from ₹590.21 Million to ₹135.36 Million, and PAT turned profitable at ₹134.16 Million compared to a loss of ₹278.06 Million YoY. EBITDA Margin improved from -81.63% to -17.15% (▲6448bps). The board also approved re-appointments of Independent Directors and the Internal Auditor, allotment of ESOP shares, a fresh ESOP grant, the 8th AGM date, and the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals.

Entero Healthcare Solutions Limited reported its Standalone Financial Results for the quarter ended March 31, 2026. Standalone Revenue was ₹789.32 Million vs ₹723.02 Million (▲9.17% YoY). EBITDA improved from a loss of ₹590.21 Million in Q4 FY25 to a loss of ₹135.36 Million in Q4 FY26. Net Profit (PAT) improved significantly from a loss of ₹278.06 Million in Q4 FY25 to a profit of ₹134.16 Million in Q4 FY26. EBITDA Margin improved from -81.63% to -17.15% (▲6448 bps YoY). The board also approved re-appointments of Independent Directors and Internal Auditor, allotment and grant of ESOPs, details for the 8th AGM, and the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals.

Standalone Revenue from operations ₹789.32Mn vs ₹723.02Mn (▲9.2% YoY). EBITDA improved from a loss of (₹590.21Mn) to a loss of (₹135.36Mn) YoY. PAT turned profitable at ₹134.16Mn vs a loss of (₹278.06Mn) YoY. EBITDA Margin improved from -81.6% to -17.2% (▲6448bps).

Consolidated Revenue ₹6,591.21Cr vs ₹5,095.78Cr (▲29.35% YoY), EBITDA ₹285.19Cr vs ₹211.05Cr (▲35.13% YoY), PAT ₹145.84Cr vs ₹107.43Cr (▲35.75% YoY). EBITDA Margin 4.33% vs 4.14% (▲19bps). The Board also approved re-appointment of Independent Directors and Internal Auditor, allotment and grant of ESOPs, an acquisition, and announced the 8th AGM.

Entero Healthcare Solutions Limited announced an earnings call to discuss its audited financial results for the quarter and year ended March 31, 2026. The call is scheduled for May 26, 2026, at 12:00 PM IST, and will be attended by the company's management including the MD & CEO, Whole Time Director & COO, and Group CFO.

Entero Healthcare Solutions Limited announced the approval of the Scheme of Amalgamation between Chethana Pharma Distributors Private Limited and CPD Pharma Private Limited (Transferor Companies) with Rada Medisolutions Private Limited (Transferee Company). The Ministry of Corporate Affairs confirmed the scheme on April 17, 2026, with an effective date of April 15, 2025. This strategic amalgamation is expected to lead to increased operational efficiencies, economies of scale, reduction in overheads and compliance costs, and simplification of the group structure.